Preventing organ-specific chemotherapy toxicity

European Journal of Cancer

Volumn 41, Issue 17, 2005, Pages 2690-2700

  Ginsberg, Jill P ^a   Womer, Richard B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alkylating agents; Anthracyclines; Cardiomyopathy; Cisplatin; Doxorubicin; Fertility; Ifosfamide; Late effects; Nephrotoxicity; Ototoxicity; Survivorship

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANALGESIC AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOPLATIN; CARNITINE; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; PHOSPHATE; PROCARBAZINE; RAZOXANE; SODIUM THIOSULFATE; VINCRISTINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AMENORRHEA; AVASCULAR NECROSIS; AZOOSPERMIA; BLOOD TOXICITY; BONE PAIN; BRAIN CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CHILDHOOD CANCER; CHRONIC TOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; COMPREHENSION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG SUBSTITUTION; EARLY MENOPAUSE; ECG ABNORMALITY; ENCAPSULATION; FANCONI RENOTUBULAR SYNDROME; FRACTIONATION; FRACTURE; FUNCTIONAL DISEASE; GERM CELL TUMOR; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GONAD DYSFUNCTION; HAND FOOT SYNDROME; HEARING LOSS; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HODGKIN DISEASE; HUMAN; HYPOPHOSPHATEMIA; IMMOBILIZATION; INTRACYTOPLASMIC SPERM INJECTION; JOINT PROSTHESIS; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; LUNG CANCER; MALE STERILITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; OLIGOMENORRHEA; OLIGOSPERMIA; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; OTOTOXICITY; OVARY CARCINOMA; OVARY INSUFFICIENCY; PHYSIOTHERAPY; POPULATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SUDDEN DEATH; SURVIVAL RATE; TESTICULAR SPERM EXTRACTION; TESTIS DISEASE; TUBULAR DYSFUNCTION; WALKING AID;

EID: 27744464905     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.05.016     Document Type: Article

References (98)

1. L.J. Steinherz, P.G. Steinherz, and C.T. Tan Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 12 1991 1672 1677
2. R. Larsen, R. Jakacki, and V. Vetter Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults Am J Cardiol 70 1992 73 77
3. J.H. Silber, R.I. Jakacki, and R.L. Larsen Increased risk of cardiac dysfunction after anthracyclines in girls Med Pediatr Oncol 21 7 1993 477 479
4. L.C. Kremer, E.C. van Dalen, and M. Offringa Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study J Clin Oncol 19 1 2001 191 196
5. J.H. Silber, and H. Kaizer Marginal analysis applied to the dose-response curve Med Pediatr Oncol 16 5 1988 344 348
6. K. Sorensen, G. Levitt, and C. Bull Anthracycline dose in childhood acute lymphoblastic leukaemia: issues of early survival versus late cardiotoxicity J Clin Oncol 15 1 1997 61 68
7. S.S. Legha, R.S. Benjamin, and B. Mackay Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion Ann Intern Med 96 2 1982 133 139
8. J. Shapira, M. Gotfried, and M. Lishner Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomised evaluation Cancer 65 4 1990 870 873
9. E.S. Casper, J.J. Gaynor, and S.I. Hajdu A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors Cancer 68 6 1991 1221 1229
10. S.E. Lipshultz, A.L. Giantris, and S.R. Lipsitz Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukaemia protocol J Clin Oncol 20 6 2002 1677 1682
11. L. Samuel, J. Cummings, and P. Shaw Daunorubicin cardiotoxicity in childhood cancer Lancet 352 9134 1998 1150
12. S.S. Bielack, R. Erttmann, and K. Winkler Doxorubicin: effect of different schedules on toxicity and anti-tumour efficacy Eur J Cancer Clin Oncol 25 5 1989 873 882
13. 2 Ann Oncol 11 8 2000 1029 1033
14. O. Lyass, B. Uziely, and R. Ben-Yosef Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 5 2000 1037 1047
15. D.W. Northfelt, B.J. Dezube, and J.A. Thommes Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial J Clin Oncol 16 7 1998 2445 2451
16. N.M. Marina, D. Cochrane, and E. Harney Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumours: a paediatric oncology group study Clin Cancer Res 8 2 2002 413 418
17. F.M. Torti, M.M. Bristow, and B.L. Lum Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy Cancer Res 46 7 1986 3722 3727
18. L.H. Wexler, M.P. Andrich, and D. Venzon Randomised trial of the cardioprotective agent ICRF-187 in paediatric sarcoma patients treated with doxorubicin J Clin Oncol 14 2 1996 362 372
19. S.E. Lipshultz, N. Rifai, and V.M. Dalton The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukaemia N Engl J Med 351 2 2004 145 153
20. S.C. Winter, and N.R. Buist Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine Am Heart J 139 2 Pt 3 2000 S63 S69
21. S. Iliceto, D. Scrutinio, and P. Bruzzi Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial J Am Coll Cardiol 26 2 1995 380 387
22. I. Rizos Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration Am Heart J 139 2 Pt 3 2000 S120 S123
23. V.R. Zales, and D.W. Benson Jr. Reversible cardiomyopathy due to carnitine deficiency from renal tubular wasting Pediatr Cardiol 16 2 1995 76 78
24. G. Strohm, C. Payne, and D. Alberts Cardiotoxic effects of doxorubicin with and without carnitine: usefulness of the mouse model in assessment Arch Path Lab Med 106 4 1982 181 185
25. S. Abdel-aleem, A.M. Karim, and W.A. Zarouk Reduced effects of L-carnitine on glucose and fatty acid metabolism in myocytes isolated from diabetic rats Horm Metab Res 29 9 1997 430 435
26. M.M. Sayed-Ahmed, S. Shaarawy, and S.A. Shouman Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine Pharmacol Res 39 4 1999 289 295
27. H.R. Yoon, Y.M. Hong, and R.L. Boriack Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats Pediatr Res 53 5 2003 788 792
28. M. Hauser, B.S. Gibson, and N. Wilson Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography Eur J Pediatr 160 10 2001 607 610
29. J.H. Silber Role of afterload reduction in the prevention of late anthracycline cardiomyopathy Pediatr Blood Cancer 44 7 2005 607 613
30. S.E. Lipshultz, and S.D. Colan Cardiovascular trials in long-term survivors of childhood cancer J Clin Oncol 22 5 2004 769 773
31. J.H. Silber, A. Cnaan, and B.J. Clark Enalapril to prevent cardiac function decline in long-term survivors of paediatric cancer exposed to anthracyclines J Clin Oncol 22 2004
32. R.B. Womer, J. Pritchard, and T.M. Barratt Renal toxicity of cisplatin in children J Pediatr 106 4 1985 659 663
33. B. Erdlenbruch, M. Nier, and W. Kern Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients Eur J Clin Pharmacol 57 5 2001 393 402
34. A.S. Petrilli, D.T. Oliveira, and V.C. Ginani Use of amifostine in the therapy of osteosarcoma in children and adolescents J Pediatr Hematol Oncol 24 3 2002 188 191
35. B. Chang, M. Nishikawa, and E. Sato L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine Arch Biochem Biophys 405 1 2002 55 64
36. N.D. Doolittle, L.L. Muldoon, and R.E. Brummett Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumours Clin Cancer Res 7 3 2001 493 500
37. R. Skinner Chronic ifosfamide nephrotoxicity in children Med Pediatr Oncol 41 3 2003 190 197
38. R. Skinner, I.M. Sharkey, and A.D. Pearson Ifosfamide, mesna, and nephrotoxicity in children J Clin Oncol 11 1 1993 173 190
39. B. Raney, L.G. Ensign, and J. Foreman Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumour Am J Pediatr Hematol Oncol 16 4 1994 286 295
40. E. Zaki, J. Springate, and M. Taub Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells Toxicol In Vitro 17 4 2003 397 402
41. J. de Kraker, M. Bierings, and M. Offringa Lack of protection of proximal tubular cells by amifostine (ethyol) in ifosfamide-containing regimens Med Pediatr Oncol 34 1 2000 78 79
42. J. Aisenberg, K. Hsieh, and G. Kalaitzoglou Bone mineral density (BMD) in long-term survivors of childhood cancer J Pediatr Hematol Oncol 20 1998 241 245
43. P. Arikoski, J. Komulainen, and P. Riikonen Reduced bone density at completion of chemotherapy for a malignancy Arch Dis Child 80 2 1999 143 148
44. B.M. Brennan, A. Rahim, and J.A. Adams Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood Br J Cancer 79 11-12 1999 1859 1863
45. S. Bhatia, N.K. Ramsay, and D. Weisdorf Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies Bone Marrow Transplant 22 1 1998 87 90
46. B. Brennan, and S.M. Shalet Reduced bone mineral density at completion of chemotherapy for a malignancy Arch Dis Child 81 4 1999 372
47. K. Ecklund, T. Laor, and A.M. Goorin Methotrexate osteopathy in patients with osteosarcoma Radiology 202 2 1997 543 547
48. I.M. van der Sluis, M.M. van den Heuvel-Eibrink, and K. Hahlen Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukaemia in childhood Med Pediatr Oncol 35 4 2000 415 420
49. B. Dawson-Hughes, S.S. Harris, and E.A. Krall Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 10 1997 670 676
50. T. Srivastava, and U.S. Alon Bisphosphonates: from grandparents to grandchildren Clin Pediatr (Phila) 38 12 1999 687 702
51. K.G. Saag, R. Emkey, and T.J. Schnitzer Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group N Engl J Med 339 5 1998 292 299
52. R.D. Barr, C.Y. Guo, and J. Wiernikowski Osteopenia in children with acute lymphoblastic leukaemia: a pilot study of amelioration with Pamidronate Med Pediatr Oncol 39 1 2002 44 46
53. L.A. Mattano Jr., H.N. Sather, and M.E. Trigg Osteonecrosis as a complication of treating acute lymphoblastic leukaemia in children: a report from the Children's Cancer Group J Clin Oncol 18 18 2000 3262 3272
54. A.J. Strauss, J.T. Su, and V.M. Dalton Bony morbidity in children treated for acute lymphoblastic leukaemia J Clin Oncol 19 12 2001 3066 3072
55. S.Y. Wei, A.N. Esmail, and N. Bunin Avascular necrosis in children with acute lymphoblastic leukaemia J Pediatr Orthop 20 3 2000 331 335
56. K. Miyanishi, T. Yamamoto, and T. Irisa A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits Rheumatology (Oxford) 40 2 2001 196 201
57. J.P. Jones Jr. Fat embolism and osteonecrosis Orthop Clin North Am 16 4 1985 595 633
58. G.J. Wang, K.C. Chung, and W.J. Shen Lipid clearing agents in steroid-induced osteoporosis J Formos Med Assoc 94 10 1995 589 592
59. G.J. Wang, Q. Cui, and G. Balian The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis Clin Orthop 370 2000 295 310
60. Q. Cui, G.J. Wang, and C.C. Su The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis Clin Orthop 344 1997 8 19
61. J.W. Pritchett Statin therapy decreases the risk of osteonecrosis in patients receiving steroids Clin Orthop 386 2001 173 178
62. J. Astrand, and P. Aspenberg Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats BMC Musculoskelet Disord 3 1 2002 19
63. S. Agarwala, A. Sule, and B.U. Pai Alendronate in the treatment of avascular necrosis of the hip Rheumatology (Oxford) 41 3 2002 346 347
64. E.J. Mackie, M. Radford, and S.M. Shalet Gonadal function following chemotherapy for childhood Hodgkin's disease Med Pediatr Oncol 27 2 1996 74 78
65. J. Heikens, H. Behrendt, and R. Adriaanse Irreversible gonadal damage in male survivors of paediatric Hodgkin's disease Cancer 78 9 1996 2020 2024
66. V. Papadakis, E. Vlachopapadopoulou, and K. Van Syckle Gonadal function in young patients successfully treated for Hodgkin disease Med Pediatr Oncol 32 5 1999 366 372
67. B.S. Charak, R. Gupta, and P. Mandrekar Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study Cancer 65 9 1990 1903 1906
68. J.U. Hassel, J.H. Bramswig, and W. Schlegel Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study Klin Padiatr 203 1991 268 272
69. S.S. Kulkarni, P.S. Sastry, and T.K. Saikia Gonadal function following ABVD therapy for Hodgkin's disease Am J Clin Oncol 20 4 1997 354 357
70. S. Viviani, A. Santoro, and G. Ragni Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD Eur J Cancer Clin Oncol 21 5 1985 601 605
71. J. Muller, J. Sonksen, and P. Sommer Cryopreservation of semen from pubertal boys with cancer Med Ped Oncol 34 2000 191 194
72. G.D. Palermo, J. Cohen, and M. Alikani Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility Fertil Steril 63 1995 1231 1240
73. S.M. Pfeifer, and C. Coutifaris Reproductive technologies 1998: options available for the cancer patient Med and Ped Oncol 33 1999 34 40
74. P.T.K. Chan, G.D. Palermo, and L.L. Veeck Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy Cancer 92 2001 1632 1637
75. M.N. Damani, V. Masters, and M.V. Meng Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection J Clin Oncol 20 2002 930 936
76. T.T. Ortin, C.A. Shostak, and S.S. Donaldson Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience Int J Radiat Oncol Biol Phys 19 1990 873 880
77. D.H. Johnson, R. Linde, and J.D. Hainsworth Effect of luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations Blood 65 1985 832 836
78. J.H. Waxman, R. Ahmed, and D. Smith Failure to preserve fertility in patients with Hodgkin's disease Cancer Chemother Pharmacol 19 1987 159 162
79. L.S. Constine Late effects of radiation therapy Paediatrician 18 1 1991 37 48
80. S.V. Nicosia, M. Matus-Ridley, and A.T. Meadows Gonadal effects of cancer therapy in girls Cancer 55 10 1985 2364 2372
81. M. Damewood, and L. Grochow Prospects for fertility after chemotherapy or radiation for neoplastic disease Fertil Steril 45 1986 443 459
82. E.I. Mayer, R.E. Dopfer, and T. Klingebiel Longitudinal gonadal function after bone marrow transplantation for acute lymphoblastic leukaemia during childhood Pediatr Transplant 3 1 1999 38 44
83. M. Hill, S. Milan, and D. Cunningham Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity J Clin Oncol 13 2 1995 387 395
84. A.B. Thomson, H.O. Critchley, and W.H. Wallace Fertility and progeny Eur J Cancer 38 12 2002 1634 1644 discussion 1645-6
85. L.E. Bath, W.H. Wallace, and H.O. Critchley Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation BJOG 109 2 2002 107 114
86. J. Byrne, J.J. Mulvihill, and M.H. Myers Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer N Engl J Med 19 1987 1315 1321
87. A. Santoro, and P. Valagussa Advances in the treatment of Hodgkin's disease Curr Opin Oncol 4 5 1992 821 828
88. A.B. Thomson, H.O. Critchley, and C.J. Kelnar Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation Best Pract Res Clin Endocrinol Metab 16 2 2002 311 334
89. Z. Blumenfeld, I. Avivi, and S. Linn Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy Hum Reprod 11 8 1996 1620 1626
90. Z. Blumenfeld Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers Mol Cell Endocrinol 187 2002 93 105
91. D. Meirow Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers Leuk Lymphoma 33 1-2 1999 65 76
92. G. Bahadur, and S.J. Steele Ovarian tissue cryopreservation for patients Hum Reprod 11 10 1996 2215 2216
93. J. Donnez, P.A. Godin, and J. Qu Gonadal cryopreservation in the young patient with gynaecological malignancy Curr Opin Obstet Gynecol 12 1 2000 1 9
94. H. Newton The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients Hum Reprod Update 4 3 1998 237 247
95. D.L. Friedman The ovary C.L. Schwartz W.L. Hobbie L.S. Constine Survivors of childhood cancer: assessment and management 2nd ed. 2005 Springer-Verlag 203 212
96. K. Oktay, E. Buyuk, and L. Veeck Embryo development after heterotopic transplantation of cryopreserved ovarian tissue Lancet 363 9412 2004 837 840
97. L. Ries, M. Smith, and J. Gurney Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995 1999 National Cancer Institute SEER Program Bethesda
98. D.L. Friedman, and A.T. Meadows Late effects of childhood cancer therapy Pediatr Clin North Am 49 5 2002 1083 1106